Cell Therapeutics Goes for Broke

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

There are Hail Mary passes thrown from midfield, and ones from deep in your own end. And then there's the one that Cell Therapeutics (Nasdaq: CTIC  ) launched yesterday from the parking lot outside the stadium.

The biotech company announced yesterday that it's appealing the Food and Drug Administration's ruling that it needs to run an additional clinical trial before it can get its cancer drug, pixantrone, approved. The company expects a decision on the appeal in the fourth quarter.

To whom does Cell Therapeutics get to appeal? Some court? No. The president? Nope. The appeal goes directly back to the FDA. Essentially, the company needs to get the agency to do a 180 and decide it made a mistake in asking for more data. Good luck with that.

Like any desperate move, there's always a chance of it working. But I only know of one company that managed to get the FDA to reverse its decision: Gilead Sciences (Nasdaq: GILD  ) convinced the agency to approve Cayston, an inhaled drug to treat lung infections in cystic fibrosis patients, after it had initially rejected the drug.

The difference is that Cayston received a positive recommendation from an FDA advisory committee. Here, an advisory panel voted 9-0 recommending that the agency not approve pixantrone. Clearing those stadium walls will be difficult.

In some ways, Cell Therapeutics has nothing to lose, especially if it's running the clinical trial concurrently with the appeal review. But it does run the danger of upsetting the FDA staffers, who probably don't appreciate having their scientific aptitude questioned.

Wyeth, just before Pfizer (NYSE: PFE  ) bought it, and sanofi-aventis (NYSE: SNY  ) both ran into similarly awkward situations when they sued the FDA to get the agency to reverse its decisions to approve generic versions of their drugs. The loss of sales because of competition from generics developed by Orchid Chemicals & Pharmaceuticals, Momenta Pharmaceuticals (Nasdaq: MNTA  ) , and Novartis (NYSE: NVS  ) forced the lawsuits, but one wonders what kind of long-term consequences they'll have for the pharma giants.

After accounting for recent debt repayments and equity financing, Cell Therapeutics has about $29.3 million in the bank, minus whatever money it has used since the end of the second quarter and $21 million in debt due next year. If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out.

Paul Elliott explains why stocks go to zero. And why you should like it.

Pfizer is a Motley Fool Inside Value choice. Momenta Pharmaceuticals is a Rule Breakers recommendation and Novartis is a Global Gains pick. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool has a disclosure policy

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1301640, ~/Articles/ArticleHandler.aspx, 10/26/2016 7:29:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
CTIC $0.41 Up +0.00 +0.20%
CTI BioPharma CAPS Rating: **
GILD $75.38 Up +0.97 +1.30%
Gilead Sciences CAPS Rating: *****
MNTA $11.53 Down -0.27 -2.29%
Momenta Pharmaceut… CAPS Rating: ****
NVS $71.13 Down -1.50 -2.07%
Novartis CAPS Rating: ****
PFE $32.40 Up +0.12 +0.37%
Pfizer CAPS Rating: ****
SNY $37.06 Down -0.33 -0.88%
Sanofi CAPS Rating: *****